OA-20 A New Circulating Tumor Cell-Based Prognostic System To Refine Patient Stratification Status of Newly Diagnosed Multiple Myeloma Patients

IF 2.7 4区医学 Q2 HEMATOLOGY

Clinical Lymphoma, Myeloma & Leukemia Pub Date : 2024-09-01 DOI:10.1016/S2152-2650(24)01861-5

Ioannis Kostopoulos, Ioannis Ntanasis-Stathopoulos, Pantelis Rousakis, Panagiotis Malandrakis, Chrysanthi Panteli, Nikolaos Tsakirakis, Evangelos Eleftherakis-Papaiakovou, Nikolaos Angelis, Vasiliki Spiliopoulou, Rodaanthi-Eleni Syrigou, Panagiotis Bakouros, Georgia Dimitrakopoulou, Despina Fotiou, Magdalini Migkou, Nikolaos Kanellias, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

引用次数: 0

查看原文本刊更多论文

OA-20 基于循环肿瘤细胞的新预后系统，用于完善新诊断多发性骨髓瘤患者的分层状况

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical Lymphoma, Myeloma & Leukemia ONCOLOGY-HEMATOLOGY

CiteScore

2.70

自引率

3.70%

发文量

1606

审稿时长

26 days

期刊介绍： Clinical Lymphoma, Myeloma & Leukemia is a peer-reviewed monthly journal that publishes original articles describing various aspects of clinical and translational research of lymphoma, myeloma and leukemia. Clinical Lymphoma, Myeloma & Leukemia is devoted to articles on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia and related disorders including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias. The main emphasis is on recent scientific developments in all areas related to lymphoma, myeloma and leukemia. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.